Surgical resection plus radiofrequency ablation for the treatment of multifocal hepatocellular carcinoma

Authors:
  • CZCheng Zhou
    Cheng Zhou
  • YPYuanfei Peng
    Yuanfei Peng
  • KZKaiqian Zhou
    Kaiqian Zhou
  • LZLan Zhang
    Lan Zhang
  • XZXiangyu Zhang
    Xiangyu Zhang
  • LYLei Yu
    Lei Yu
  • JHJie Hu
    Jie Hu
  • FCFeiyu Chen
    Feiyu Chen
  • SQShuangjian Qiu
    Shuangjian Qiu
  • JZJian Zhou
    Jian Zhou
  • JFJia Fan
    Jia Fan

Abstract
Background: To compare the efficacy and safety of surgical resection plus radiofrequency ablation (SR-RFA) with transarterial chemoembolization (TACE) in patients with multifocal hepatocellular carcinoma (HCC) beyond the Milan criteria. Methods: From 2009 to 2015, a total of 469 consecutive patients with multifocal HCC beyond the Milan criteria (≤5 nodules) treated with SR-RFA (n=59) or TACE (n=410) were analyzed. Their overall survival (OS) rate was compared through propensity score matching (PSM) analysis at a ratio of 1:2, and 141 patients were identified (SR-RFA, n=47; TACE, n=94). Subgroup analysis was conducted according to factors associated with treatment options. Results: Before PSM, the 1-, 2- and 3-year OS rates were 81.5%, 68.3% and 64.3% in the SR-RFA group and 58.7%, 35.5% and 24.4% in the TACE group, respectively (all PConclusions: SR-RFA provides better a long-term survival rate than TACE for patients with multifocal HCC beyond the Milan criteria. SR-RFA may serve as an alternative treatment for patients with multifocal HCC in a selected patient population.